Company intelligence
OS Therapies
Targeting Osteosarcoma, Breast Cancer and other Solid Tumors to prevent HER2-metastasis and destroy solid tumors.
About OS Therapies
OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors. OST-HER2 is completing a PhIIb clinical trial in 4Q2024 with significantly improved Event Free Survival (EFS), and early Overall Survival (OS). OST-tADC is a ph-sensitive novel pre-clinical Drug Conjugate that uses proprietary (IP) Silicon to cover and link the multiple payloads until they are delivered to the acidic cancer environment, dissolving the Silicon - delivering and activating the payloads.
Verified activity
Signals from OS Therapies
8 published signals
Legal & Regulatory
OS Therapies continues preparations for regulatory submissions and the confirmatory Phase 3 Metastatic Osteosarcoma Program trial.
Reported by OS Therapies
Capital & Finance
OS Therapies announced receipt of $3.15 million in VAT refunds through its wholly owned subsidiary, OS Therapies UK, Ltd., with at least an additional $7.2 million in VAT and R&D Tax Credits pending.
Reported by OS Therapies
Research & Knowledge
OS Therapies announced an interim 3-year overall survival data analysis from its Phase 2b trial for OST-HER2-treated patients in fully resected, pulmonary metastatic osteosarcoma, showing a statistically significant benefit of 71.2% overall survival rate compared to 45.8% in a published historical control group.
Reported by OS Therapies
Research & Knowledge
OS Therapies provided an update on its OST-HER2 metastatic osteosarcoma program, outlining expected clinical and regulatory milestones through the remainder of 2026.
Reported by OS Therapies
Research & Knowledge
OS Therapies expects interim 3-year overall survival data, an FDA Type C Statistical Methods Meeting, and a U.K. MHRA Statistical Methods Scientific Advice Meeting to be expected in September 2026.
Reported by OS Therapies
Research & Knowledge
OS Therapies expects final 3-year overall survival data, an FDA Pre-BLA Meeting, a BLA submission in the U.S., and CMAA submissions in the U.K. and Europe to be expected in Q4.
Reported by OS Therapies
Research & Knowledge
OS Therapies expects RMAT and Rolling Review decisions to follow the FDA meeting.
Reported by OS Therapies
Research & Knowledge
OS Therapies expanded its research through OS Animal Health, with the OST-HER2 platform being evaluated in canine osteosarcoma.
Reported by OS Therapies